SmartTRAK spotlights CytexOrtho, the AAOS 2024 OrthoPitch winner, as it develops its biodegradable implant to address early joint degeneration. 

In this interview with SmartTRAK, CytexOrtho CEO Brad Estes, PhD, discusses the company’s cartilage repair implant, ReNewHip, an engineered bicomponent implant used for cartilage regeneration.

To find out more about CytexOrtho and its technology, click the image below to watch the video (26:37 min). A link to download a transcript of the interview is also provided below.

SmartTRAK: Hi, this is Emily Meng with SmartTrak. Today I'm here with CytexOrtho CEO Brad Estes. Thanks, Brad, for joining me today.

Bradley Estes: Yeah, I'm happy to be here. Thanks for having me.

So, we'll just jump in and start asking you some questions. Let’s start with can you tell me about yourself and your background and how you got started with CytexOrtho.

BE: Yeah, it was kind of a circuitous route to get here. I started my career in the Medtech industry with Sofamor Danek, which was eventually acquired by Medtronic, and kind of did a lot of R&D in the heyday of spine, I like to say it, and was even on the team that did BMP-2. So that was a lot of fun seeing the role of a biologic in orthopedics and what that could really do to change the way patients are treated. And so I spent about eight years in Medtronic and then I left industry, came to academia, did a PhD at Duke and kind of retooled and learned the molecular biology, the stem cell biology, the tissue engineering and just kind of gained a whole new skill set. I got to work with some really great people and that kind of set us off on our journey of where we are today and kind of tie in some product development experience with science and having the right time and the right people and the right funding to push forward with CytexOrtho. And I'm sure I caused more questions in that response than answered, but I'm happy to fill in the gaps, too.

Can you tell us a little bit about CytexOrtho and what you guys are doing, and specifically, I guess, for ReNew Hip, since that's your product that is under development.

BE: So, our goal from the beginning has been to treat that patient that currently has no solutions. I'm talking the patient in their 30s, 40s or 50s that have early-stage hip disease, but they have no solutions right now. Their plight is kind of sad if you think about it. They go see their doctor, they have some hip pain, they're starting to not be able to do the things they want to do. And so, they take some ibuprofen, do some PT, and let's come back and see me in a year and that progresses for about seven or eight years typically. That's what our data tells us. That patient is just living with more chronic pain and increasing disability over that eight years until finally they can't take it anymore and then they replace their hip. And so, our technology is ...

Click the button below to download the complete transcript of our interview with Brad Estes, CEO of CytexOrtho, conducted by  SmartTRAK analyst Emily Meng.

SmartTRAK spotlights SentryX, a clinical-stage biopharmaceutical company developing a non-opioid platform for the treatment of acute pain after surgery,​ in an interview at AAOS 2025 in San Diego. 

SentryX Co-Founder and Chief Medical Officer Jorrit-Jan (JJ) Verlaan, MD, discusses the company’s novel implantable anesthetic for spine surgery applications in an interview with SmartTRAK at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual meeting in San Diego. The hydrogel works with all types of small-molecule drugs with a release profile that can be tailored to specific clinical needs and surgical procedures.

To find out more about SentryX and its novel technology, listen to the following video. (13:37 min.) A link to download a transcript of the interview is also provided below.

Hi, I’m Kristine Jacques, a Senior Analyst with SmartTRAK Spine. We are here at the American Academy of Orthopedic Surgeons 2025. I’m sitting down with Dr. JJ Verlaan, a spine surgeon, co-founder, and Chief Medical Officer for SentryX, a Netherlands-based company developing a groundbreaking non-opioid solution for postoperative pain. First of all, Dr. Verlaan, I want to congratulate you on being one of the top four finalists inthe OrthoPitch Event at the Academy this year. It’s quite an honor.

Dr. Jorrit-Jan Verlaan: Thank you very much.

Thank you so much for sitting down with the SmartTRAK team. I’d like to start out with you telling us about your background and how the idea came about for the Hydrogel and starting SentryX.

JJV: Thank you so much. I'm a surgeon from Utrecht in the Netherlands. I've been practicing spine surgery from the moment I got board-certified. Rapidly, during work in my practice, I noticed that patients after spine surgery are all in a lot of pain. The moment that you realize that, and you actually ask the patients how much pain they have, on a scale of 0-10 they sometimes respond with a 12. I had a chat with an anesthesiologist one day in between surgeries. We were discussing what is out there right now to treat pain. The anesthesiologist, she told me, "Well, not much, really. We're still relying on opioids. Maybe we could do something with local anesthetics, but it's not working long enough at this point." That kind of sparked the idea of doing something locally to treat the pain, but differently. Soon after, I hit upon the idea that we're developing right now in the company.

How far along are you in the development?

JJV: We started in 2017, together with my partner Bas Oosterman who is the CEO of the company. First it was just a raw idea. We soon found out that this idea, it had never been done before. That gave us the opportunity to actually file IP on our solution and go for it. At the end of 2017  we officially founded the company. We got our first employees and collaborated with a renowned institute on biofabrication. We developed a new ...

Click the button below to download and read the complete transcript of SmartTRAK's interview with SentryX Co-Founder and CMO Jorrit-Jan (JJ) Verlaan, MD, conducted by Kris Jacques, SmartTRAK Sr Analyst.

Wound GM Kris Flinn and Senior Analysts Elizabeth Anderson and Jay Merkel discuss the impact of delay and how industry players may choose to react.

On April 11, 2025, Centers for Medicare and Medicaid Services announced that the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers Final Local Coverage Determinations (LCDs) effective date will be delayed until January 1, 2026. In this video (16:43 minutes), SmartTRAK Wound GM Kris Flinn and Senior Analysts Elizabeth Anderson and Jay Merkel discuss the impact of delay, and how industry players may choose to react.

The SmartTRAK Wound Team will be in attendance at the upcoming SAWC Spring conference in Grapevine, TX (April 30 to May 4). Please register here to meet the team.

Recently, SmartTRAK's VP of Sales, Joe Mish, sat down with the Alpha Sophia podcast to discuss the impacts of data on the Medtech market. Hosted by Alpha Sophia founder & CEO Paul-Lukas Hoffschmidt, the podcast dives deep into the cutting-edge of MedTech innovations and commercial trends.

In this video, Joe breaks down how SmartTRAK delivers critical market intelligence to MedTech companies, helping them track trends, product performance and market changes. He explores how the Alpha Sophia partnership enhances real-time intelligence, enabling businesses to quickly act on insights, stay ahead of industry shifts, adapt to changing market dynamics and maintain a competitive edge in an evolving market. Click the video below to watch the podcast.

SmartTRAK and Alpha Sophia together offers a data-driven, AI-powered solution for commercial teams in the healthcare sector. Click the button below to watch our webinar titled "Growth in 2025: More Than Targeting" outlining how SmartTRAK and Alpha Sophia can accelerate business opportunities by combining deep market insights with advanced targeting strategies, ultimately enabling sales teams to engage more effectively with the right customers at the right time.